Price
Financials
Consolidated, Rs crore| Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 323 | 185 | 273 | 387 | 229 | 120 | 203 | 158 | 152 |
| Expenses | 283 | 128 | 229 | 354 | 240 | 637 | 233 | 188 | 164 |
| Operating Profit | 40 | 57 | 44 | 34 | -11 | -517 | -30 | -31 | -12 |
| OPM % | 12% | 31% | 16% | 9% | -5% | -430% | -15% | -19% | -8% |
| Other Income | 17 | -1 | 6 | 4 | 19 | 740 | 17 | 1 | 2 |
| Interest | 23 | 48 | 37 | 49 | 69 | 120 | 23 | 45 | 22 |
| Depreciation | 9 | 8 | 9 | 11 | 10 | 6 | 11 | 9 | 10 |
| Profit before tax | 26 | 1 | 4 | -23 | -72 | 96 | -47 | -84 | -43 |
| Tax % | 20% | -4% | 29% | 1% | 2% | -0% | 0% | 0% | 7% |
| Net Profit | 21 | 1 | 3 | -23 | -74 | 97 | -47 | -84 | -46 |
| EPS in Rs | 10.22 | 0.41 | 1.53 | -11.36 | -35.85 | 47.01 | -22.82 | -40.69 | -22.41 |
| Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 15m | Jun 2014 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 449 | 551 | 620 | 722 | 960 | 1,329 | 1,626 | 997 | 633 |
| Expenses | 371 | 446 | 538 | 599 | 789 | 1,130 | 1,354 | 1,433 | 1,222 |
| Operating Profit | 78 | 105 | 82 | 123 | 171 | 199 | 272 | -436 | -589 |
| OPM % | 17% | 19% | 13% | 17% | 18% | 15% | 17% | -44% | -93% |
| Other Income | 7 | 8 | 41 | 4 | 4 | 28 | 31 | 754 | 760 |
| Interest | 16 | 24 | 41 | 53 | 66 | 102 | 155 | 276 | 211 |
| Depreciation | 9 | 11 | 12 | 17 | 29 | 34 | 44 | 36 | 37 |
| Profit before tax | 61 | 79 | 70 | 57 | 80 | 92 | 104 | 6 | -77 |
| Tax % | 14% | 11% | 13% | 16% | 21% | 21% | 21% | 209% | |
| Net Profit | 53 | 70 | 61 | 47 | 64 | 72 | 82 | -7 | -80 |
| EPS in Rs | 28.41 | 37.10 | 32.26 | 26.25 | 31.27 | 35.19 | 40.12 | -3.18 | -38.91 |
| Dividend Payout % | 9% | 7% | 8% | 11% | 10% | 9% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 10% | 1% | -41% | ||
| Compounded Profit Growth | % | % | % | -390% | ||
| Stock Price CAGR | 0% | % | % | % | ||
| Return on Equity | % | -2% | -9% | -46% |
| Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 19 | 21 | 21 | 21 | 21 |
| Reserves | 305 | 346 | 373 | 462 | 610 | 680 | 749 | 753 |
| Borrowings | 237 | 342 | 499 | 574 | 832 | 1,081 | 1,344 | 848 |
| Other Liabilities | 113 | 91 | 122 | 138 | 279 | 219 | 380 | 667 |
| Total Liabilities | 673 | 798 | 1,013 | 1,192 | 1,741 | 2,000 | 2,492 | 2,288 |
| Fixed Assets | 140 | 169 | 171 | 490 | 648 | 706 | 691 | 707 |
| CWIP | 137 | 163 | 252 | 66 | 95 | 191 | 273 | 305 |
| Investments | 37 | 88 | 50 | 66 | 10 | 20 | 3 | 3 |
| Other Assets | 359 | 377 | 539 | 570 | 989 | 1,082 | 1,526 | 1,273 |
| Total Assets | 673 | 798 | 1,013 | 1,192 | 1,741 | 2,000 | 2,492 | 2,288 |
| Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 71 | 21 | 136 | -91 | 66 | 15 | 17 | 1,175 |
| Cash from Investing Activity | -88 | -108 | -35 | -161 | -151 | -171 | -63 | -56 |
| Cash from Financing Activity | 38 | 110 | -34 | 184 | 273 | 43 | -4 | -676 |
| Net Cash Flow | 20 | 22 | 67 | -68 | 188 | -113 | -51 | 443 |
| Free Cash Flow | -30 | -44 | 34 | -241 | -149 | -171 | -95 | 1,096 |
| CFO/OP | 91% | 29% | 177% | -66% | 49% | 18% | 15% | -272% |
| Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Jun 2013 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 92 | 105 | 99 | 107 | 94 | 89 | 61 |
| Inventory Days | 154 | 115 | 107 | 151 | 189 | 155 | 107 | 73 |
| Days Payable | 65 | 45 | 39 | 40 | 37 | 47 | 53 | 55 |
| Cash Conversion Cycle | 189 | 162 | 172 | 210 | 259 | 202 | 144 | 79 |
| Working Capital Days | 158 | 140 | 163 | 186 | 112 | 140 | 93 | -97 |
| ROCE % | 16% | 12% | 12% | 12% | 12% | 13% | -4% |
Fundamentals
Market Cap₹ 78.0 Cr.
Current Price₹ 38.0
Book Value₹ 342
ROCE-3.56 %
ROE-45.6 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-41%
Compounded Profit Growth (TTM)-390%
Consolidated figures.
Valuation
P/E, 3-year average11.92x
P/B, 3-year average1.22x
P/E, 5-year average10.55x
P/B, 5-year average1.33x
Profitability
Operating margin (excl. other income)14.99%
Operating margin (incl. other income)17.09%
EBITDA margin26.48%
Pre-tax margin-14.88%
Net profit margin-15.14%
Net margin, latest quarter-52.91%
ROE10.86%
ROCE11.90%
ROA3.86%
ROE, 3-year average11.25%
ROCE, 3-year average11.59%
ROA, 3-year average4.24%
ROE, 5-year average14.02%
ROCE, 5-year average12.98%
ROA, 5-year average5.79%
ROIC (approx.)7.38%
Tax rate21.04%
Other income / net worth3.97%
Growth
Sales growth (latest year)38.51%
Profit growth (latest year)12.52%
Sales CAGR, 3 years28.91%
Sales CAGR, 5 years24.22%
Profit CAGR, 3 years5.91%
Profit CAGR, 5 years6.49%
Sales growth QoQ-22.26%
Sales growth YoY (latest quarter)-59.20%
Per share
EPS (TTM)Rs -52.20
EPS (latest year)Rs 35.08
EPS (latest quarter)Rs -40.57
EPS, 3-year averageRs 30.84
EPS, 5-year averageRs 32.35
Book value per shareRs 340.16
Sales per shareRs 344.79
Cash flow per shareRs 7.16
Free cash flow per shareRs 532.13
Dividend per share (latest year)Rs 3.00
Dividend per share, 3-year averageRs 3.00
Dividend per share, 5-year averageRs 2.80
Dividends
Dividend payout8.54%
Dividend payout, 3-year average9.87%
Dividend payout, 5-year average8.82%
Efficiency
Asset turnover0.66x
Fixed asset turnover1.88x
Inventory turnover2.51x
Inventory days145 days
Debtor days94 days
Debtors turnover3.89x
Creditor days55 days
Cash conversion cycle79 days
Working capital days-97 days
Leverage
Total debtRs 1,081 Cr
Cash and bankRs 154 Cr
Net debtRs 927 Cr
Debt to equity1.54x
Net debt / EBITDA4.93x
Interest coverage0.59x
Owners' fund to total sources35.03%
Debt to assets54.04%
Cash flow
Cash from Operating Activity (latest year)Rs 15 Cr
Cash from Investing Activity (latest year)Rs -171 Cr
Cash from Financing Activity (latest year)Rs 43 Cr
Net Cash Flow (latest year)Rs -113 Cr
Free cash flow (latest year)Rs 1,096 Cr
FCFE (approx.: FCF + change in debt)Rs 1,344 Cr
Cash from ops / profit, 5 years5.49x
Sales to cash flow90.10x
Statement figures
Net sales (TTM)Rs 710 Cr
Net sales (latest year)Rs 1,329 Cr
Sales (latest quarter)Rs 158 Cr
Operating profit excl. other income (latest year)Rs 199 Cr
Operating profit (latest quarter)Rs -31 Cr
Other income (TTM)Rs 777 Cr
EBITDA (TTM)Rs 188 Cr
PBDT (TTM)Rs -70 Cr
Profit before tax (TTM)Rs -106 Cr
Tax (latest year)Rs 19 Cr
Net profit (TTM)Rs -108 Cr
Net profit (latest year)Rs 72 Cr
Net profit (latest quarter)Rs -84 Cr
Depreciation (TTM)Rs 36 Cr
Depreciation (latest quarter)Rs 9 Cr
Interest (TTM)Rs 258 Cr
Cost of goods sold (latest year)Rs 736 Cr
Total expenditure (latest year)Rs 1,130 Cr
Total income (latest year)Rs 1,357 Cr
Share capitalRs 21 Cr
ReservesRs 680 Cr
Shareholders' fundsRs 701 Cr
Total assetsRs 2,000 Cr
Net blockRs 706 Cr
Capital work in progressRs 191 Cr
InvestmentsRs 20 Cr
ReceivablesRs 341 Cr
InventoryRs 293 Cr
Other liabilitiesRs 219 Cr
Shares outstanding (crore)2.06
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 4 of 8| explain | Weak cash conversion Cash from operations was -6% of net profit over the last 3 years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2015Sales ₹152 Cr -33.6% vs Mar 2014.
Net loss ₹46 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Elder Pharmaceuticals Ltd?
Elder Pharmaceuticals Ltd (532322) has a market capitalisation of Rs 78.0 Cr. at the close.
What were Elder Pharmaceuticals Ltd's latest quarterly results?
In the Mar 2015 quarter, Elder Pharmaceuticals Ltd sales was Rs 152 Cr (-33.6% vs Mar 2014) with a net loss of Rs 46 Cr.